Navigation Links
Stopping a receptor called 'nogo' boosts the synapses
Date:3/18/2008

kholm showed that exercise reduces the abundance of the nogo receptor in the brain. Gigers work provides a molecular framework that brings the disparate findings together.

The findings could also explain something that has puzzled scientists, said Giger. Mice with damaged spinal cords that have been treated with compounds designed to knock out the nogo receptor seem to improve a bit, even though scientists have never been able to demonstrate nerve regrowth in those mice. It may be that their improvement instead is coming through the signal-boosting effect in the synapses.

While its tempting to think that knocking down the nogo receptor is a simple process that would help people under all circumstances by boosting their brain power, Giger points out that the molecule is not only found at synapses but also along axons, where scientists believe it plays an important role limiting the sprouting of nerve fibers. Any effort to reduce the nogo receptor will have to be studied thoroughly to watch for other effects.


'/>"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Fugitive cancer cells can be blocked by stopping blood cells that aid them
2. Physicians focus on stopping pain epidemic
3. First 90 Days After Stopping Plavix Most Dangerous
4. New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Familys Feet
5. New Sedona Stopping Diabetes Program
6. Common drug for stopping preterm labor may be harmful for babies
7. Hands2GO(R) Hand Sanitizer Offers Alcohol-Free Alternative to Stopping the Spread of Flu at School and Work
8. On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack
9. Stopping Tysabri May Worsen MS
10. Stopping Statins After Stroke Doubles Death Risk
11. Pain receptor in brain may be linked to learning and memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 DISCcert ... materials showing how to use 17 DISC applications at ... is a natural progression. , The July 25 & ... the top 17 ways of applying DISC. The time-tested, ... certified graduates. The user-friendly DISC training materials ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... The Orsiro stent, which is a novel stent ... non-inferiority to the Xience Prime everolimus-eluting stent for ... loss at nine months in the results of ... , The BIOFLOW-II substudy used intravascular ultrasound (IVUS) ... neointimal hyperplasia and stent apposition at nine months ...
(Date:5/21/2013)... Hillsboro, OR (PRWEB) May 21, 2013 ... curing systems at the 20th Annual IMI European ... As a proven market leader, Phoseon continues to invest ... while accelerating the adoption of UV LED curing in ... of product families on the market offering both air ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
... The Lancet Supports Cardio-Protective Potential of Aleglitazar - , ... will start Phase III clinical investigations for aleglitazar, its innovative ... morbidity and mortality in high risk patients with type 2 ... II SYNCHRONY study published today in The Lancet(1) ...
... , Customizable Survival Kit Offers One Stop for ... Local Healthcare Market Drivers and Health Plan Trends ... a leading provider of managed care market intelligence, ... shifts in membership at the state level than ...
... the company that will become public from the planned ... today filed a second amendment to its Form 10 ... that includes information about its post-spin board of directors ... under a consent decree for its Alaris(R) infusion products. ...
... United Spinal Association ( www.UnitedSpinal.org ) presents the ... ) , the region,s premiere lifestyle-enhancing Expo designed to ... aging Americans. , , The Independence Expo will ... at the Suffolk Community College Sports & Exhibition Complex in ...
... PSI-7851 was generally safe and well tolerated in Phase 1a ... results from single ascending and multiple ascending dose trials are ... June 9 Pharmasset, Inc. (Nasdaq: VRUS ) ... study and begun dosing in a multiple ascending dose trial ...
... ... its Multilayer Aneurysm Repair System (MARS) has received CE Mark approval for treating patients ... ... announced today that it has received CE Mark approval for the commercial sale of ...
Cached Medicine News:Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 2Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 3Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 4Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 5Health News:Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 3Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 4Health News:United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 3Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 4Health News:Cardiatis Multilayer Aneurysm Repair System, MARS, Receives CE Mark Approval for Treating Peripheral Aneurysms 2
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)... NEW YORK , May 21, 2013 ... market research report is available in its ... Changing Regulatory and Reimbursement Scenario for Medical ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   ... Devices in the US Market ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... prioritization -, LOUISVILLE, Colo., Dec. 10 ... announced an operational restructuring to align,critical resources ... partner for Replidyne,s late-stage antibiotic, faropenem,medoxomil (faropenem), ... exploring additional corporate development opportunities., The ...
... outcomes for premature babies, FORT WORTH, Texas, ... Now, they are helping improve the care of,premature ... care unit recently implemented the use of the ... results in decreasing the,incidence of chronic lung disease ...
Cached Medicine Technology:Replidyne Provides Strategic Update 2Replidyne Provides Strategic Update 3Replidyne Provides Strategic Update 4Replidyne Provides Strategic Update 5Replidyne Provides Strategic Update 6Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe 2
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • Not available with casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: